

KING PHARMACEUTICALS INC

Form 8-K/A

March 03, 2006

EXPLANATORY NOTE

This Amendment No. 1 to the Current Report on Form 8-K/A of King Pharmaceuticals, Inc. (the Company) amends the Current Report on Form 8-K that was filed by the Company with the Securities and Exchange Commission (the Commission) on February 17, 2006 (the Initial Form 8-K). This Amendment No. 1 to the Initial Form 8-K is being filed to amend the statement in Item 1.01 of the Initial Form 8-K that copies of the Ramipril Patent License Agreement, the Ramipril Application License Agreement, the Product Supply Agreement and the Generic Distribution Agreement would be filed with the Company s Annual Report on Form 10-K for the twelve-month period ending December 31, 2005.

ITEM 1.01 Entry into a Material Definitive Agreement.

Copies of the Ramipril Patent License Agreement, the Ramipril Application License Agreement, the Product Supply Agreement and the Generic Distribution Agreement will be filed with the Company s Quarterly Report on Form 10-Q for the quarter ending March 31, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

King Pharmaceuticals, Inc.

By: /s/ Brian A. Markison

Brian A. Markison
President and Chief Executive Officer

Date: March 2, 2006